ISSN: 2578-465X
Authors: Mohini Agrawal
Zoledronate, a bisphosphonate, is commonly used as an annual intravenous infusion, primarily in the treatment of osteoporosis. Ocular adverse effects have been documented and orbital inflammation is one of the most severe. It may clinically manifest by eyelid edema, conjunctival congestion, chemosis, restricted ocular motility, pain, diplopia, and reduced vision. It usually has asymmetric involvement and rarely associated with anterior uveitis, scleritis, episcleritis or conjunctivitis. Prompt treatment is likely to have favorable outcomes. Though, the treatment of choice remains systemic corticosteroids, we highlight a case who developed orbital inflammation after Zoledronate-infusion and improved after topical corticosteroids administration.
Keywords: Orbital Inflammation; Zolendronate; Corticosteroids; Bisphosphonates
